Skip to main content

Dog leucocyte antigen (DLA) class II haplotypes and risk of canine diabetes mellitus in specific dog breeds

Abstract

Background

Canine diabetes mellitus (DM) is a common endocrine disease in domestic dogs. A number of pathological mechanisms are thought to contribute to the aetiopathogenesis of relative or absolute insulin deficiency, including immune-mediated destruction of pancreatic beta cells. DM risk varies considerably between different dog breeds, suggesting that genetic factors are involved and contribute susceptibility or protection. Associations of particular dog leucocyte antigen (DLA) class II haplotypes with DM have been identified, but investigations to date have only considered all breeds pooled together. The aim of this study was to analyse an expanded data set so as to identify breed-specific diabetes-associated DLA haplotypes.

Methods

The 12 most highly represented breeds in the UK Canine Diabetes Register were selected for study. DLA-typing data from 646 diabetic dogs and 912 breed-matched non-diabetic controls were analysed to enable breed-specific analysis of the DLA. Dogs were genotyped for allelic variation at DLA-DRB1, -DQA1, -DQB1 loci using DNA sequence-based typing. Genotypes from all three loci were combined to reveal three-locus DLA class II haplotypes, which were evaluated for statistical associations with DM. This was performed for each breed individually and for all breeds pooled together.

Results

Five dog breeds were identified as having one or more DLA haplotype associated with DM susceptibility or protection. Four DM-associated haplotypes were identified in the Cocker Spaniel breed, of which one haplotype was shared with Border Terriers. In the three breeds known to be at highest risk of DM included in the study (Samoyed, Tibetan Terrier and Cairn Terrier), no DLA haplotypes were found to be associated with DM.

Conclusions

Novel DLA associations with DM in specific dog breeds provide further evidence that immune response genes contribute susceptibility to this disease in some cases. It is also apparent that DLA may not be contributing obvious or strong risk for DM in some breeds, including the seven breeds analysed for which no associations were identified.

Plain English summary

Diabetes mellitus (DM) affects approximately 1 in 300 dogs in the UK and is much more common in some breeds than others. Multiple factors and biological processes are involved in canine DM. There is preliminary evidence that genetic factors may explain why some breeds are predisposed to, or protected from, developing this disease. Previous evidence has indicated that the immune system may contribute to destruction of the pancreas in diabetic dogs, similar to that seen in human type 1 DM. A collection of genes encoding the dog leucocyte antigens (DLA) play a critical role in regulating immune responses and previous studies have implicated a role for these genes in canine DM. However, no investigations have yet been conducted in individual pedigree dog breeds. This study compared variation within the DLA genes of diabetic and non-diabetic dogs for 12 different breeds. In 5 breeds, increased risk for or protection from DM was associated with particular DLA gene variations. However, no associations were identified in the three breeds at highest risk of DM included in the study (Samoyed, Tibetan Terrier and Cairn Terrier). This study supports a role for DLA-encoded immune regulation in the development of DM in certain dog breeds. Future studies of gene function in single breeds will help identify causal variants and mechanisms, which may lead to improved diagnosis and management of affected dogs.

Background

Canine DM is a relatively common endocrinopathy encountered in routine veterinary clinical practice, with a UK prevalence of 0.32–0.34% [1, 2]. Cases are diagnosed on the basis of persistent fasting hyperglycaemia, persistent glycosuria and compatible clinical signs [3]. Virtually all diabetic dogs require daily insulin injections [3], although the precise cause of the pancreatic beta cell dysfunction/destruction remains elusive.

Most cases of canine DM are diagnosed in dogs aged between 5 and 12 years of age [1]. A classification system has been proposed, based on the underlying pathogenesis of the hyperglycaemia, namely either insulin deficiency diabetes (IDD) or insulin resistance diabetes (IRD) [4]. Further classification nomenclature has recently been proposed by the European Society for Veterinary Endocrinology (ESVE) project ALIVE (Agreeing Language in Veterinary Endocrinology) [5]. Apart from female entire dogs, which can develop a form of IRD during dioestrus or pregnancy, most cases of canine DM can be classified as IDD [4]. However, the underlying pathogenesis of insulin deficiency is likely to be complex and heterogeneous. DM is likely to be the consequence of a decline in pancreatic beta cell mass, resulting from increased beta cell destruction and/or impaired beta cell regeneration. Histopathological studies have reported reduced populations of beta cells in the pancreatic tissue of diabetic dogs [6, 7]. This has prompted research into whether beta cell loss occurs due to immune-mediated destruction, as is the case in human Type 1 DM (T1D) [8]. The most common autoantibodies identified in human T1D (against insulin, GAD-65 and IA-2) have been detected in a small proportion of diabetic dogs [9,10,11,12]; other studies have failed to detect autoantibodies [13]. Lymphocytic infiltration of pancreatic islets, as seen at the onset of human T1D [14, 15], has rarely been reported in dogs [7, 13]. Therefore, the role of the adaptive immune system in canine DM remains uncertain. It has also been proposed that canine DM might be more similar to human latent autoimmune diabetes of adults (LADA) rather than T1D [16]. This is a more slowly progressive immune-mediated destruction of pancreatic beta cells occurring in combination with other non-immunological risk factors, leading to reduced beta cell mass and insulin deficiency later in life.

The striking pattern of breed predispositions for canine DM strongly suggests that genetic risk factors contribute to disease susceptibility. Breeds such as the Samoyed, Yorkshire Terrier, Australian Terrier and Miniature Schnauzer have all been reported to be at high risk in independent studies, whereas the Boxer, Golden Retriever and German Shepherd Dog are considered to be at low risk of developing DM [1, 2, 17, 18]. A large number of diabetes susceptibility genes, each contributing relatively small effects, have been identified in human T1D [19], Type 2 DM (T2D) [20] and monogenic DM [21]. This has prompted candidate gene studies in canine DM, which have largely focussed on T1D genes involved with immune function [22,23,24,25] and human monogenic diabetes genes [26].

Genes encoded within the major histocompatibility complex (MHC) play critical roles in the regulation of the adaptive immune response in higher species. These roles include their involvement in the setting of baseline immune tolerance, allowing distinction of ‘self’ antigens from ‘non-self’ antigens, and also influencing the degree of immune response that develops to particular antigens. A striking feature of many of MHC loci is their extreme levels of gene polymorphism. Certain MHC class II gene polymorphisms are highly associated with the development of autoimmune conditions and other immune-mediated diseases in humans [27, 28] and other mammals including dogs [29, 30].

Canine MHC genes, known as the dog leucocyte antigen (DLA) genes are found on chromosome 12. There are four functional class II MHC genes in the dog: DLA-DRA1, -DRB1, -DQA1 and -DQB1 [31]. These encode cell-surface heterodimers which bind antigenic peptides in a peptide binding groove and present these to T cell receptors for regulation of the adaptive immune response. DLA-DRA1 appears to be monomorphic, while the other three functional class II genes are highly polymorphic, resulting in diversity in the antigen binding capabilities of the class II molecules. The extensive linkage disequilibrium in this region results in particular combinations of alleles being found together as preferential haplotype combinations. Therefore, three-locus DLA class II haplotypes of DLA-DRB1, -DQA1 and -DQB1 are often used to study the relationship of the DLA to disease.

Just as some human HLA gene polymorphisms and haplotype combinations are present or absent in some ethnic groups, or are seen at different gene frequencies in different populations, the same is observed across different pedigree dog breeds, but to even more extreme levels [32, 33]. Furthermore, specific HLA-types influencing disease risk vary between different human ethnic populations [34, 35]. A previous candidate gene study, investigating the role of the MHC in canine DM, identified four DLA haplotypes that were associated with disease risk or protection [25]. That study compared DLA class II alleles and haplotypes in pooled populations of dogs with canine DM to unaffected dogs, but did not have sufficient sample sizes to enable analysis by individual breed. However, pooling of data between breeds can obscure differences in DM pathogenesis that may exist among breeds. Therefore, studying the role of DLA haplotypes within individual breeds can improve understanding of the role of DLA genes in particular breeds and help to identify those cases where underlying pathology may be similar.

The aim of the current study was to determine whether specific DLA haplotypes are associated with risk or protection from DM in individual dog breeds and whether combined analysis of all 12 breeds would support the findings of the previous study. Identifying whether DLA genes influence the risk of canine DM will improve understanding of whether this endocrinopathy is likely to have an immune-mediated pathogenesis in certain breeds.

Methods

Study population

EDTA blood samples from UK diabetic dogs, submitted by veterinary surgeons to the Royal Veterinary College (RVC) Canine Diabetes Register with informed consent (Ethics Review Board number: URN 2017 1685–3), were used for this study. A diagnosis of DM was made on the basis of persistent hyperglycaemia, glucosuria and consistent clinical signs. Dogs were either newly diagnosed or had been receiving insulin treatment for a variable period of time. Following diagnostic testing, residual blood samples were made available for research. Samples from female entire diabetic dogs were excluded, as these were potentially affected with dioestrus diabetes. Where age data were available, diabetic dogs < 6 months old at diagnosis were also excluded as these were potentially affected with a form of juvenile DM. Blood samples from non-diabetic dogs were obtained from the RVC DNA Archive and the Companion Animal DNA Archive (University of Manchester). Control samples with a recorded clinical history of autoimmune disease were also excluded.

To facilitate breed-specific analysis, 12 different dog breeds were selected in which there were samples from at least 20 cases, and where the number of controls was equal to or greater than the number of cases. The sample size for each breed included in the study, and the published odds ratio for UK population-based breed-associated risks for DM [36], are summarised in Table 1.

Table 1 DM risk for the specific breeds analysed [36] and samples sizes

DLA class II typing

Dogs were genotyped for three DLA class II loci: DLA-DRB1, DLA-DQA1 and DLA-DQB1. The DLA data used in a previous study [25] was also included in the present study. The DLA-typing methods and primers used for these samples are described in detail elsewhere [25]. The additional samples used in this study were similarly analysed by DNA sequence-based typing of exon 2 for each DLA locus, performed using a touchdown PCR protocol. Primers are listed in Supplementary Table 1 [37,38,39]. Purification of PCR products was performed (ExoSAP-IT PCR Clean-up Reagent, Applied Biosystems or GenElute PCR Clean-Up Kit, Sigma-Aldrich) prior to DNA sequencing using a standard Sanger sequencing protocol. Sequencing data were analysed by either SBTengine (GenDx, Genome Diagnostics B.V.) or MatchTools/MatchTools Navigator (Applied Biosystems). DNA sequences were aligned to a consensus sequence and each polymorphic site analysed electronically or manually. Sequences were electronically aligned against a reference sequence library to assign the correct allele for each locus. DLA haplotypes were subsequently assigned, based on established DLA-types for each breed [40].

Statistical analysis

Haplotype counts were performed in Microsoft Excel for cases and controls of each breed. Statistical analysis was carried out using R software (R Foundation for Statistical Computing). Contingency Tables were used to calculate odds ratios; confidence intervals were determined using Fisher’s Exact Test. Odds ratios were considered to be significant when the upper and lower confidence intervals did not cross 1.

Results

DLA haplotype frequencies observed in each breed are summarised in Table 2 (higher risk breeds) and Table 3 (lower risk breeds). For ease of reference, haplotype IDs were arbitrarily assigned to the 30 most common haplotypes observed in the study (Supplementary Table 2). The two most common DLA haplotypes observed in the study population were haplotype 1 (DRB1*001:01--DQA1*001:01--DQB1*002:01; 13.6% cases vs. 12.1% controls) and haplotype 6 (006:01--005:01:1--007:01; 14.1% cases vs. 10.9% controls). These were also two of the three most commonly observed haplotypes in the previous study [25].

Table 2 Haplotype frequencies (%) observed in the six highest risk breeds included in the study
Table 3 Haplotype frequencies (%) observed for the six lowest risk breeds included in the study

The frequency of DLA haplotypes in cases and controls was analysed separately for individual breeds. Eight DLA haplotypes were significantly different comparing cases and controls, across five breeds (Table 4). Four haplotypes (IDs: 6, 7, 14 & 19) in the Cocker Spaniel breed were associated with DM susceptibility or protection. Haplotype 6 (DLA 006:01--005:01:1--007:01) was associated with DM risk (OR = 6.3, 95% CI: 3.1–13.7). In contrast, haplotype 7 (006:01--005:01:01--020:01), which only differs from risk haplotype 6 at the DQB1 locus, was associated with protection against DM (OR = 0.30, 95% CI = 0.1–0.7). Similarly, haplotype 1 (001:01--001:01--002:01), which was associated with increased DM risk in Labrador Retrievers, only differs at the DQB1 locus from haplotype 2 (001:01--001:01--036:01), which was associated with lower DM risk in West Highland White Terriers (WHWT).

Table 4 Breed-specific analysis (only significant haplotypes and breeds shown)

Haplotype 19 (015:01--006:01--020:02) was found to be a DM protective haplotype in both the Cocker Spaniel and Border Terrier breeds. No other DLA haplotypes were associated with risk or protection in more than one breed. Furthermore, no risk or protective haplotypes were identified for the three breeds at greatest risk of DM included in the study: the Samoyed, Tibetan Terrier and Cairn Terrier.

All of the haplotypes identified as having some association with DM in an individual breed were also carried by multiple other breeds included in this study (Table 4). The most common haplotype in the Cocker Spaniel breed (haplotype 6; 006:01--005:01:1--007:01) was also found in all other breeds, apart from the four breeds with the highest risk of developing DM (Samoyed, Cairn Terrier, Tibetan Terrier and Miniature Schnauzer) and the Border Terrier. This haplotype is common among the general dog population, being found in 70% of dog breeds, albeit at a wide range of frequencies (L.J. Kennedy; personal communication).

A combined analysis of all 12 breeds was performed, in order to compare findings more directly with the observations made in Kennedy et al. (2006). This analysis revealed four haplotypes associated with DM risk or protection (Table 5). Three of these haplotypes had been associated with DM risk/protection in the individual analysis of the Cocker Spaniel breed (IDs 6, 7 and 14; Table 4). The remaining haplotype from the combined analysis was not associated with DM risk in any individual breeds. None of the haplotypes from the combined analysis had been significantly associated with risk of DM in the previous study [25], in which a smaller number of dogs, representing a wider range of breeds, had been examined together.

Table 5 Combined analysis of all 12 breeds (only significant haplotypes shown)

Analysis of high-risk breeds

Given that no haplotypes were identified as significantly different between diabetic cases and non-diabetic controls for the breeds at highest risk of canine DM (Samoyed, Tibetan Terrier and Cairn Terrier), the DLA profiles for these high-risk breeds were examined in order to identify any breed-associated patterns that may relate to their predisposition to DM. The DLA haplotypes observed in each of these three breeds are shown in Table 6.

Table 6 DLA haplotypes identified in cases and controls for the three highest-risk breeds included in the study

The Samoyed breed was found to have a relatively restricted DLA profile, with only seven different haplotypes. Haplotype 18 (015:01--006:01--019:01--054:02), which carries two alleles at the DQB1 locus, was only found in the Samoyed dogs in this study and accounted for more than half of the haplotypes identified in both cases (63.25%) and controls (65%) of this breed. A second haplotype, (040:01--010:01--019:01, no haplotype ID) was also found only in Samoyeds, although at a relatively low frequency (4.4% cases, 3.6% controls). The second most common haplotype in Samoyeds, haplotype 10 (009:01--001:01--008:02) differs by a single non-synonymous base-pair change from haplotype 9 (009:01--001:01--008:01:1), which was also observed in the two other highest risk breeds.

The Tibetan and Cairn Terriers were found to have a more diverse DLA profile than Samoyeds, with 13 different haplotypes being identified in each breed. Six haplotypes were identified exclusively within the Tibetan Terrier breed. All of these were found at low frequency except haplotype 22 (015:01-- 006:01--026:01), which represented 7.5% of diabetic and 18.8% of control haplotypes, and haplotype 30 (079:01--001:01--002:01) which represented 30% of diabetic and 26.3% of control haplotypes. Haplotype 1 (001:01--001:01--002:01), which was found to confer diabetes risk in Labrador Retrievers (Table 4), was also identified in Tibetan and Cairn Terriers. However, this was one of the most common haplotypes observed in the study. No haplotypes were identified exclusively within the Cairn Terrier breed.

Discussion

The primary aim of this study was to identify whether DLA class II haplotypes are associated with risk or protection from DM in individual UK dog breeds. A secondary aim was to determine whether a pooled analysis of all 12 breeds included in the current study would support the findings of the previous study by Kennedy et al. (2006). Our study indicated that no DLA haplotypes were associated with risk of DM in the ‘highest DM risk’ breeds (Samoyed, Cairn Terrier, Tibetan Terrier and Miniature Schnauzer). Five ‘moderate DM risk’ breeds were found to possess DLA haplotypes that were associated with risk or protection from DM; all of these haplotypes were also present in other breeds, although only one DLA haplotype was associated with protection from DM in more than one breed (haplotype 19; DLA-DRB1*015:01--DQA1*006:01--DQB1*020:02, found to confer protection in Cocker Spaniel and Border Terrier breeds). These findings provide further evidence for the role of MHC class II and the adaptive immune system in the pathogenesis of canine DM in some breeds and suggest that the disease is likely to be heterogeneous among breeds.

As a result of its popularity, the Labrador Retriever was the most highly represented breed in this study (111 cases / 240 controls). It is a breed at a moderate [36] to neutral [2] risk of developing DM. In this breed, DLA haplotype 1 (001:01--001:01--002:01) was found to be associated with increased risk of DM (OR = 1.59, 95% CI = 1.02–2.47), which suggests that this particular DLA-type might play a role in the pathogenesis of beta cell loss/dysfunction in this breed. This DLA haplotype has previously been associated with increased risk of hypothyroidism in Gordon Setters [41] as well as primary hypoadrenocorticism (Addison’s disease; AD) in WHWT and Leonberger breeds [42]. Notably, both hypothyroidism associated with lymphocytic thyroiditis and primary hypoadrenocorticism are considered to have an autoimmune basis and demonstrate breed differences in susceptibility [43, 44]. Additionally, the DLA-DRB1*001:01 allele has been found to confer risk of anal furunculosis in GSDs [45, 46], suggesting that this particular DRB1 allele may be important in dysregulated inflammatory disease processes.

In the second most highly represented breed, the WHWT (133 cases/150 controls), which is also the breed at fifth highest risk of DM in this study, DLA haplotype 2 (001:01--001:01--036:01) was associated with protection from DM (95% CI = 0–0.95). This haplotype was identified in 6 controls (2% of controls) and not in any diabetic dogs, which supports a role for this haplotype in protecting against DM in this breed. However, because it was only identified in only 2% of controls and the 95% CI is very wide (0–0.95), this association should be interpreted with caution and further investigated in a larger cohort of WHWTs. A similar observation was made by a study of DLA class II haplotypes in AD [42]: the same haplotype (001:01--001:01--036:01) was identified solely in the control population of WHWTs (0 cases; 6 controls). However, this may be due to the WHWT control population being much larger than the case population in that study (43 cases; 166 controls).

Haplotype 2, associated with protection from DM in WHWTs, differs only at the DQB1 locus from haplotype 1, associated with increased risk of DM in Labrador Retrievers, suggesting that the DQB1 locus influences disease susceptibility, or that it is in linkage disequilibrium with other susceptibility loci within the MHC region. Non-synonymous variants in a single locus may influence disease risk by modifying the antigen binding capabilities of the MHC molecules [47], particularly if these variants occur in the hypervariable regions. For example, in human T1D, polymorphisms at positions 56 and 57 of the DQB chain are associated with either disease susceptibility or resistance, according to the amino acid changes in the peptide binding groove [48]. It has been suggested that many risk haplotypes associated with organ-specific autoimmune disease in dogs carry either DQA1*001:01--DQB1*002:01 or DQA1*001:01--DQB1*008:02 haplotypes [42]. The first of these DQ haplotypes is present in haplotype 1 in this study (001:01--001:01--002:01), associated with DM in the Labrador Retriever, however, the second was not present in any haplotypes associated with DM in any of the 12 breeds in the present study. Further examination of the role of these DQ haplotypes in autoimmune disease is warranted, particularly in relation to the effect of variants on the ability of MHC molecules to bind autoantigens and the influence of this on generation of immune tolerance or autoimmunity.

The Cocker Spaniel, a breed with moderate risk for DM [2, 36], is predisposed to autoimmune disease [49,50,51,52]. The DLA population profile of Cocker Spaniels is relatively restricted, with most dogs of this breed carrying DRB1*006:01--DQA1*005:01:1 with either DQB1*007:01 or DQB1*020:01 [32]. This restricted DLA profile might be related to a relative hypersensitivity or impaired tolerance towards self-antigen. In the current study, Cocker Spaniels were found to carry one DLA haplotype associated with increased risk of DM and three haplotypes associated with protection from disease (Table 4), suggesting that the MHC plays an important role in determining an individual’s susceptibility to DM in this breed. The DLA haplotype conferring risk, haplotype 6 (006:01--005:01:1--007:01), is the most common haplotype in the breed and is also carried, to some extent, in other dog breeds. In contrast, haplotype 7 (006:01--005:01:1--020:01) confers protection, again implicating the DQB1 locus in disease susceptibility. A previous study of chronic pancreatitis in English Cocker Spaniels also found that the DLA haplotype containing DQB1*007:01 was present in a significantly greater proportion of cases, whereas the haplotype containing DQB1*020:01 was more prevalent in the control population without evidence of pancreatitis [54]. The authors of that study proposed that this suggests a predisposition of English Cocker Spaniels for immune-mediated disease more generally, since DQB1*007:01 has also been implicated in primary immune-mediated haemolytic anaemia [30, 53]. The present study supports this assertion. The DQB1*007:01 allele differs from DQB1*020:01 by 5 amino acids in a hypervariable region of DQB1 exon 2, which has been previously defined [55]. The effect of these amino acid changes on autoantigen binding and presentation by MHC molecules deserves further investigation.

Interestingly, no DLA haplotype associations with DM were identified in the three breeds at highest risk of canine DM: the Samoyed, Tibetan Terrier and Cairn Terrier. It is possible that DM in these breeds is more commonly of a non-immune-mediated aetiology and the MHC plays a less significant role. However, an alternative explanation is that MHC alleles and haplotypes predisposing to DM are not significantly different between cases and controls but are present at high frequency among the breed and exert a ‘fixed breed risk’ rather than individual risk. The possibility of genes, such as the MHC, exerting a fixed risk of DM within certain breeds could be investigated by comparing breeds at high and low risk of DM rather than comparing cases and controls within single breeds. The most common haplotype in the Samoyed breed in this study, haplotype 18 (015:01--006:01--019:01--054:02), was present at high frequency among both cases and controls (63.25% case and 65% control haplotypes) and is exclusively found in this breed. It is possible that this haplotype contributes to the high risk of DM in the Samoyed breed, with other genetic and environmental factors combining to determine whether an individual develops DM. Similarly, six haplotypes were identified exclusively within the Tibetan Terrier breed. Those present at higher frequency (haplotypes 25 and 30) may contribute to the increased risk of DM in this breed.

The two most common haplotypes observed in the study (haplotypes 1 and 6) were also two of the most common identified in the study by Kennedy et al. (2006). This may reflect the fact that Labrador Retrievers and certain terrier breeds (WHWT and Yorkshire Terrier) were highly represented in both studies and a high proportion of dogs in these breeds carry one or both of these haplotypes. Furthermore, these two haplotypes are common in the general dog population (L.J. Kennedy, personal communication).

In the combined analysis with all breeds pooled together, four haplotypes were associated with risk or protection from DM (Table 5). However, three of these were associated with risk or protection in Cocker Spaniels, therefore the combined associations may have been strongly influenced by the haplotype frequencies in this breed. None of the three-locus DLA haplotype associations with canine DM in Kennedy et al. (2006) were replicated in the present study. However, the 2-locus DRB1--DQA1 haplotype associated with risk of canine DM in the previous analysis (015--006) is present in a protective haplotype (haplotype 16; 015:01--006:01--003:01) in this study. The difference between the two studies is likely to be due to the different number and range of breeds included. Previously, a more heterogeneous population of 87 breeds had been included at lower sample numbers per breed, compared with the current study with a more limited breed profile (n = 12 breeds), but each with a minimum of 20 cases and an expanded population of breed-matched controls. The DLA haplotype diversity is known to be restricted within certain breeds but very diverse between breeds [32, 33], therefore altering the relative breed frequencies will impact on the representation of DLA haplotypes in the study population. However, the diverse observations of the two studies highlights how pooling of haplotypes between different breeds can conceal differences among breeds and further emphasizes the need for breed-specific approaches to study the genetics of canine complex disease, such as DM.

There are a number of limitations to the present study which must be considered. The use of sequence-based typing of the MHC has been questioned by a study suggesting that associations found by this method cannot be replicated by a SNP genotyping method [56]. However, SBT allows DNA to be sequenced directly from PCR and the use of specialist software (SBT-Engine, GenDx, Utrecht, the Netherlands) for allele assignment allows reproducibility of results and reduces human error. It is possible that sequencing exon 2 of DLA alleles may have identified associated, but not causative, polymorphisms [57], due to the high degree of linkage disequilibrium in the canine genome. Therefore, follow-up functional studies will be required to determine whether the DLA haplotype associations identified here represent linked or causative polymorphisms. Future work would also benefit from additional samples to allow analysis in a broader range of breeds and a consistent number of cases/controls of each breed. It would also be interesting to carry out pedigree studies in diabetic dogs, considering the MHC haplotypes and disease history of relatives of DM cases. In the future, it may be possible to evaluate an expanded MHC profile (including other genes within this region) from whole genome sequencing and increase the size of the study cohorts through the use of publicly accessible genotyping data for different dog breeds.

The identification of ‘protective’ DLA haplotypes should also be interpreted with caution. In some cases, an allele is present at low frequency in a population, only because a risk allele is present at a relatively high frequency, rather than because it confers protection from disease. This may be the case in Cocker Spaniels in the present study, where there is one dominant ‘risk’ haplotype and the ‘protective’ haplotypes occur at much lower frequency. Larger sample numbers, or exclusion of cases with the dominant risk haplotype in future studies, may help to clarify the importance of the protective associations. Protective MHC haplotypes are documented in human T1D, for example the DRB1*15:01--DQA1*01:02--DQB1*06:02 (HLA-DR2) haplotype which exerts a dominant protective effect in Caucasians [58]. Carriage of this haplotype is highly protective [59], although the effect is not consistent across all ethnic populations and there is some evidence to suggest that the protective effect is modified by other HLA loci [60].

Given the important role of the MHC in the adaptive immune system, the associations identified here support an immune-mediated component to the pathogenesis of disease in some cases of canine DM in some breeds. The associations identified in the Cocker Spaniel, a breed predisposed to autoimmune disease, warrant further follow-up to determine what proportion of diabetic Cocker Spaniels may have an immune-mediated component to the disease. In the DM high-risk breeds, with no DLA associations identified in this study, there remains a high degree of uncertainty surrounding the aetiology of their hyperglycaemia. This once again emphasises the heterogenous nature of canine DM, with different mechanisms leading to beta cell loss and insulin deficiency from breed to breed, and immune-mediated disease playing a role in only a proportion of dogs. In the absence of strong histological or serological evidence of an immune-mediated process being responsible for many cases of canine DM, our data suggest that focus of future investigations in this area should be on breeds where DLA genes do appear to influence disease risk. This could apply to future studies of autoantibodies in canine DM, which previously have not consistently identified circulating autoantibodies [9,10,11,12]. In addition, pancreatic necropsy studies in dogs euthanased at or around the time of diagnosis of DM may provide further insight into the histopathological changes in the pancreas during early stages of disease, and could be supported by breed clubs in those breeds where DM is particularly prevalent.

The present findings also emphasise the need for a better understanding of the mechanistic role of canine MHC class II proteins in immunity/immunopathology, particularly in relation how allelic variants associated with disease risk or protection modify the structure and function of MHC molecules, including the peptides they can present. The class II MHC genes confer > 50% genetic risk in human T1D [61] and may also be highly important in immune-mediated forms of canine DM. However, the heterogeneity identified between breeds in this study highlights the need to consider the other genetic and environmental factors which interact to determine an individual’s overall disease risk.

Although these findings are not yet relatable to clinical diagnosis or management of canine DM, they highlight the importance of work to better classify the phenotypes/subtypes of canine DM, similar to the subdivision of human DM patients into T1D, T2D and other forms of disease. This will help to strengthen the power of future analyses by reducing the risk of including disease phenocopies (individuals with the same clinical signs but different pathogenesis to their disease) in study cohorts. Furthermore, a better understanding of how MHC haplotypes influence risk of canine DM may allow stratification of cohorts for clinical research projects according to genotype, which will improve statistical power. In the era of precision medicine, it is possible that canine DM cases where immune-mediated pancreatic destruction can be proven to be responsible for clinical signs may benefit from different management strategies compared to cases with insulin antagonism/resistance or exocrine pancreatic disease.

Availability of data and materials

The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

References

  1. 1.

    Davison LJ, Herrtage ME, Catchpole B. Study of 253 dogs in the United Kingdom with diabetes mellitus. Vet Rec. 2005;156(15):467–71.

    CAS  Article  PubMed  Google Scholar 

  2. 2.

    Mattin M, O’Neill D, Church D, McGreevy PD, Thomson PC, Brodbelt D. An epidemiological study of diabetes mellitus in dogs attending first opinion practice in the UK. Vet Rec. 2014;174(14):349.

    CAS  Article  PubMed  Google Scholar 

  3. 3.

    Behrend E, Holford A, Lathan P, Rucinsky R, Schulman R. 2018 AAHA diabetes management guidelines for dogs and cats. J Am Anim Hosp Assoc. 2018;54(1):1–21.

    Article  PubMed  Google Scholar 

  4. 4.

    Catchpole B, Ristic JM, Fleeman LM, Davison LJ. Canine diabetes mellitus: can old dogs teach us new tricks? Diabetologia. 2005;48(10):1948–56.

    CAS  Article  PubMed  Google Scholar 

  5. 5.

    The mouse tumor biology database. http://tumor.informatics.jax.org/mtbwi/index.do. Accessed 20 May 2013.

  6. 6.

    Gepts W, Toussaint D. Spontaneous diabetes in dogs and cats - a pathological study. Diabetologia. 1967;3(2):249–65.

    CAS  Article  PubMed  Google Scholar 

  7. 7.

    Shields EJ, Lam CJ, Cox AR, Rankin MM, Van Winkle TJ, Hess RS, et al. Extreme beta-cell deficiency in pancreata of dogs with canine diabetes. PLoS One. 2015;10(6):1–19.

    Article  CAS  Google Scholar 

  8. 8.

    Todd JA. Etiology of type 1 diabetes. Immunity. 2010;32:457–67.

    CAS  Article  PubMed  Google Scholar 

  9. 9.

    Davison LJ, Weenink SM, Christie MR, Herrtage ME, Catchpole B. Autoantibodies to GAD65 and IA-2 in canine diabetes mellitus. Vet Immunol Immunopathol. 2008;126(1–2):83–90.

    CAS  Article  PubMed  Google Scholar 

  10. 10.

    Davison LJ, Walding B, Herrtage ME, Catchpole B. Anti-insulin antibodies in diabetic dogs before and after treatment with different insulin preparations. J Vet Intern Med. 2008;22(6):1317–25.

    CAS  Article  PubMed  Google Scholar 

  11. 11.

    Holder AL, Kennedy LJ, Ollier WER, Catchpole B. Breed differences in development of anti-insulin antibodies in diabetic dogs and investigation of the role of dog leukocyte antigen (DLA) genes. Vet Immunol Immunopathol. 2015;167(3–4):130–8.

    CAS  Article  PubMed  Google Scholar 

  12. 12.

    Kim JH, Furrow E, Ritt MG, Utz PJ, Robinson WH, Yu L, et al. Anti-insulin immune responses are detectable in dogs with spontaneous diabetes. PLoS One. 2016;11(3):e0152397.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. 13.

    Ahlgren KM, Fall T, Landegren N, Grimelius L, Von Euler H, Sundberg K, et al. Lack of evidence for a role of islet autoimmunity in the aetiology of canine diabetes mellitus. PLoS One. 2014;9(8).

  14. 14.

    Gepts W. Pathologic anatomy of the pancreas in juvenile diabetes mellitus. Diabetes. 1965;14(10):619–33.

    CAS  Article  PubMed  Google Scholar 

  15. 15.

    Foulis AK, Liddle CN, Farquharson MA, Richmond JA, Weir RS. The histopathology of the pancreas in type I (insulin-dependent) diabetes mellitus: a 25-year review of deaths in patients under 20 years of age in the United Kingdom. Diabetologia. 1986;29(5):267–74.

    CAS  Article  PubMed  Google Scholar 

  16. 16.

    Fleeman LM, Rand JS. Management of Canine Diabetes. Vet Clin North Am Small Anim Pract. 2001;31(5):855–80.

    CAS  Article  PubMed  Google Scholar 

  17. 17.

    Fall T, Hamlin HH, Hedhammar Å, Kämpe O, Egenvall A. Diabetes mellitus in a population of 180,000 insured dogs: incidence, survival, and breed distribution. J Vet Intern Med. 2007;21(6):1209–16.

    Article  PubMed  Google Scholar 

  18. 18.

    Yoon S, Fleeman LM, Wilson BJ, Mansfield CS, McGreevy P. Epidemiological study of dogs with diabetes mellitus attending primary care veterinary clinics in Australia. Vet Rec. 2020;187:e22.

  19. 19.

    Pociot F, Lernmark Å. Genetic risk factors for type 1 diabetes. Lancet. 2016;387(10035):2331–9.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  20. 20.

    Willemsen G, Ward KJ, Bell CG, Christensen K, Bowden J, Dalgård C, et al. The concordance and heritability of type 2 diabetes in 34,166 twin pairs from international twin registers: the discordant twin (DISCOTWIN) consortium. Twin Res Hum Genet. 2015;18(6):762–71.

    Article  PubMed  Google Scholar 

  21. 21.

    Misra S, Owen KR. Genetics of monogenic diabetes: present clinical challenges. Curr Diab Rep. 2018;18(12):141.

    Article  PubMed  PubMed Central  Google Scholar 

  22. 22.

    Short AD, Catchpole B, Kennedy LJ, Barnes A, Fretwell N, Jones C, et al. Analysis of candidate susceptibility genes in canine diabetes. J Hered. 2007;98(5):518–25.

    CAS  Article  PubMed  Google Scholar 

  23. 23.

    Short AD, Saleh NM, Catchpole B, Kennedy LJ, Barnes A, Jones CA, et al. CTLA4 promoter polymorphisms are associated with canine diabetes mellitus. Tissue Antigens. 2010;4:242–52.

    Article  CAS  Google Scholar 

  24. 24.

    Short AD, Catchpole B, Kennedy LJ, Barnes A, Lee AC, Jones CA, et al. T cell cytokine gene polymorphisms in canine diabetes mellitus. Vet Immunol Immunopathol. 2009;128(1–3):137–46.

    CAS  Article  PubMed  Google Scholar 

  25. 25.

    Kennedy LJ, Davison LJ, Barnes A, Short AD, Fretwell N, Jones CA, et al. Identification of susceptibility and protective major histocompatibility complex haplotypes in canine diabetes mellitus. Tissue Antigens. 2006;68(6):467–76.

    CAS  Article  PubMed  Google Scholar 

  26. 26.

    Short AD, Holder A, Rothwell S, Massey J, Scholey R, Kennedy LJ, et al. Searching for “monogenic diabetes” in dogs using a candidate gene approach. Canine Genet Epidemiol. 2014;1(1):8.

    Article  PubMed  PubMed Central  Google Scholar 

  27. 27.

    Trowsdale J. The MHC, disease and selection. Immunol Lett. 2011;137(1–2):1–8.

    CAS  Article  PubMed  Google Scholar 

  28. 28.

    Thorsby E, Lie BA. HLA associated genetic predisposition to autoimmune diseases: Genes involved and possible mechanisms. Transpl Immunol. 2005;14(3–4 SPEC. ISS):175–82.

    CAS  Article  PubMed  Google Scholar 

  29. 29.

    Kennedy LJ, Quarmby S, Happ GM, Barnes A, Ramsey IK, Dixon RM, et al. Association of canine hypothyroidism with a common major histocompatibility complex DLA class II allele. Tissue Antigens. 2006;68(1):82–6.

    CAS  Article  PubMed  Google Scholar 

  30. 30.

    Kennedy LJ, Barnes A, Ollier WER, Day MJ. Association of a common dog leucocyte antigen class II haplotype with canine primary immune-mediated haemolytic anaemia. Tissue Antigens. 2006;68(6):502–8.

    CAS  Article  PubMed  Google Scholar 

  31. 31.

    Debenham SL, Hart EA, Ashurst JL, Howe KL, Quail MA, Ollier WE, Binns MM. Genomic sequence of the class II region of the canine MHC: comparison with the MHC of other mammalian species. Genomics. 2005;85:48–59.

    CAS  Article  PubMed  Google Scholar 

  32. 32.

    Kennedy LJ, Barnes A, Happ GM, Quinnell RJ, Bennett D, Angles JM, et al. Extensive interbreed, but minimal intrabreed, variation of DLA class II alleles and haplotypes in dogs. Tissue Antigens. 2002;59(3):194–204.

    CAS  Article  PubMed  Google Scholar 

  33. 33.

    Angles JM, Kennedy LJ, Pedersen NC. Frequency and distribution of alleles of canine MHC-II DLA-DQB1, DLA-DQA1 and DLA-DRB1 in 25 representative American kennel Club breeds. Tissue Antigens. 2005;66(3):173–84.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  34. 34.

    Nyaga DM, Vickers MH, Jefferies C, Perry JK, O’Sullivan JM. The genetic architecture of type 1 diabetes mellitus. Mol Cell Endocrinol. 2018;477:70–80.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  35. 35.

    Noble JA, Johnson J, Lane JA, Valdes AM. HLA class II genotyping of African American type 1 diabetic patients reveals associations unique to African haplotypes. Diabetes. 2013;62(9):3292–9.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  36. 36.

    Catchpole B, Adams JP, Holder AL, Short AD, Ollier WER, Kennedy LJ. Genetics of canine diabetes mellitus : are the diabetes susceptibility genes identified in humans involved in breed susceptibility to diabetes mellitus in dogs ? Vet J. 2013;195(2):139–47.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  37. 37.

    Wagner JL, Burnett RC, DeRose SA, Storb R. Molecular analysis and polymorphism of the DLA-DQA gene. Tissue Antigens. 1996;48(3):199–204.

    CAS  Article  Google Scholar 

  38. 38.

    Wagner JL, Burnett RC, Works JD, Storb R. Molecular analysis of DLA-DRB1 polymorphism. Tissue Antigens. 1996;48(5):554–61.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  39. 39.

    Wagner JL, Hayes-Lattin B, Works JD, Storb R. Molecular analysis and polymorphism of the DLA-DQB genes. Tissue Antigens. 1998;52(3):242–50.

    CAS  Article  Google Scholar 

  40. 40.

    Kennedy LJ, Barnes A, Short A, Brown JJ, Lester S, Seddon J, et al. Canine DLA diversity: 1. New alleles and haplotypes. Tissue Antigens. 2007;69(Suppl 1):272–88.

    CAS  Article  PubMed  Google Scholar 

  41. 41.

    Ziener ML, Dahlgren S, Thoresen SI, et al. Genetics and epidemiology of hypothyroidism and symmetrical onychomadesis in the Gordon setter and the English setter. Canine Genet Epidemiol. 2015;2:12.

  42. 42.

    Gershony LC, Belanger JM, Short AD, Le M, Hytönen MK, Lohi H, Famula TR, Kennedy LJ, Oberbauer AM. DLA class II risk haplotypes for autoimmune diseases in the bearded collie offer insight to autoimmunity signatures across dog breeds. Canine Genet Epidemiol. 2019;6:2.

    Article  PubMed  PubMed Central  Google Scholar 

  43. 43.

    Boag AM, Catchpole B. A review of the genetics of hypoadrenocorticism. Top Companion Anim Med. 2014;29(4):96–101.

    Article  PubMed  Google Scholar 

  44. 44.

    Graham PA, Refsal KR, Nachreiner RF. Etiopathologic findings of canine hypothyroidism. Vet Clin North Am Small Anim Pract. 2007;37(4):617–31.

    Article  PubMed  Google Scholar 

  45. 45.

    Kennedy LJ, O’Neill T, House A, Barnes A, Kyöstilä K, Innes J, et al. Risk of anal furunculosis in German shepherd dogs is associated with the major histocompatibility complex. Tissue Antigens. 2008;71(1):51–6.

    CAS  PubMed  Google Scholar 

  46. 46.

    Barnes A, O’Neill T, Kennedy LJ, Short AD, Catchpole B, House A, et al. Association of canine anal furunculosis with TNFA is secondary to linkage disequilibrium with DLA-DRB1*. Tissue Antigens. 2009;73(3):218–24.

    CAS  Article  PubMed  Google Scholar 

  47. 47.

    Tsai S, Santamaria P. MHC class II polymorphisms, autoreactive T-cells, and autoimmunity. Front Immunol. 2013;4:321.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  48. 48.

    Todd JA, Bell JI, Mcdevitt HO. HLA-DQ beta gene contributes to susceptibility and resistance to insulin-dependent diabetes mellitus. Nature. 1987;329:599–604.

    CAS  Article  PubMed  Google Scholar 

  49. 49.

    Daminet S, Paradis M. Evaluation of thyroid function in dogs suffering from recurrent flank alopecia. Can Vet J. 2000;41(9):699–703.

    CAS  PubMed  PubMed Central  Google Scholar 

  50. 50.

    Sanchez RF, Innocent G, Mould J, Billson FM. Canine keratoconjunctivitis sicca: disease trends in a review of 229 cases. J Small Anim Pract. 2007;48(4):211–7.

    CAS  Article  PubMed  Google Scholar 

  51. 51.

    Klag AR, Giger U, Shofer FS. Idiopathic immune-mediated hemolytic anemia in dogs: 42 cases (1986-1990). J Am Vet Med Assoc. 1993;202(5):783–8.

    CAS  PubMed  Google Scholar 

  52. 52.

    Bell JS. Hereditary hypothyroidism: understanding the disease process. Tufts’ Canine and Feline Breeding and Genetics Conference; 2003.

  53. 53.

    Threlfall AJ, Boag AM, Soutter F, Glanemann B, Syme HM, Catchpole B. Analysis of DLA-DQB1 and polymorphisms in CTLA4 in cocker spaniels affected with immune-mediated haemolytic anaemia. Canine Genet Epidemiol. 2015;2(1).

  54. 54.

    Bazelle J, Aguirre-Hernandez J, Watson P, Kennedy LJ. Association between chronic pancreatitits and dog leucocyte antigen haplotypes in the English cocker spaniel. 2013 ACVIM forum research abstracts program. J Vet Intern Med. 2013;27(3):604–756.

    Article  Google Scholar 

  55. 55.

    Kennedy LJ, Altet L, Angles JM, Barnes A, Carter SD, Francino O, Gerlach JA, Happ GM, Ollier WE, Polvi A, Thomson W, Wagner JL. Nomenclature for factors of the dog major histocompatibility system (DLA), 1998: first report of the ISAG DLA nomenclature committee. Anim Genet. 2000;31(1):52–61.

    CAS  Article  PubMed  Google Scholar 

  56. 56.

    Safra N, Pedersen NC, Wolf Z, Johnson EG, Liu HW, Hughes AM, et al. Expanded dog leukocyte antigen (DLA) single nucleotide polymorphism (SNP) genotyping reveals spurious class II associations. Vet J. 2011;189(2):220–6.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  57. 57.

    Seddon JM, Berggren KT, Fleeman LM. Evolutionary history of DLA class II haplotypes in canine diabetes mellitus through single nucleotide polymorphism genotyping. Tissue Antigens. 2010;75(3):218–26.

    CAS  Article  PubMed  Google Scholar 

  58. 58.

    Pugliese A, Gianani R, Moromisato R, Awdeh ZL, Alper CA, Erlich HA, et al. HLA-DQB1*0602 is associated with dominant protection from diabetes even among islet cell antibody-positive first-degree relatives of patients with IDDM. Diabetes. 1995;44(6):608–13.

    CAS  Article  PubMed  Google Scholar 

  59. 59.

    Erlich H, Valdes AM, Noble J, Carlson JA, Varney M, Concannon P, et al. HLA DR-DQ haplotypes and genotypes and type 1 diabetes risk analysis of the type 1 diabetes genetics consortium families. Diabetes. 2008;57(4):1084–92.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  60. 60.

    Valdes G, Thomson J, Graham M, Zarghami B, Mcneney I, Kockum A, Smith M, Lathrop A, Steenkiste RJ, Dorman JS, Noble JA, Hansen AMA. D6S265*15 marks a DRB1*15, DQB1*0602 haplotype associated with attenuated protection from type 1 diabetes mellitus. Diabetologia. 2005;48:2540–3.

    CAS  Article  PubMed  Google Scholar 

  61. 61.

    Rotter JI, Landaw EM. Measuring the genetic contribution of a single locus to a multilocus disease. Clin Genet. 1984;26:529–42.

    CAS  Article  PubMed  Google Scholar 

Download references

Acknowledgements

With thanks to the UK Companion Animal DNA Archive, who extracted the DNA from many of the samples. We are also grateful to all the owners of dogs with diabetes and control dogs, who gave permission for their dogs to participate in this study.

Funding

ALD’s PhD studentship is supported by LIDo Doctoral Training Program (BBSRC; BB/J014567/1) and by Dechra Ltd. (industrial partner for iCASE studentship). LJD is supported by an MRC Clinician Scientist Fellowship (MR/R007977/1). The study was partly supported by the European Commission (FP7-LUPA, GA-201370). The UK Canine Diabetes Register and Archive has been supported by the Kennel Club Charitable Trust, BSAVA Petsavers, and MSD Animal Health.

Author information

Affiliations

Authors

Contributions

ALD carried out DLA typing of some canine samples, analysed the full dataset and wrote the first draft manuscript. JM and LK carried out DLA typing of the majority of canine samples. LK, BC, and LJD and WO proposed the project, revised the manuscript and provided substantial scientific contributions. All the authors approved the final version of the manuscript.

Corresponding author

Correspondence to L. J. Kennedy.

Ethics declarations

Ethics approval and consent to participate

EDTA blood samples from UK diabetic dogs were submitted by veterinary surgeons to the Royal Veterinary College Canine Diabetes Register with informed consent (Ethics Review Board number: URN 2017 1685–3).

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Denyer, A.L., Massey, J.P., Davison, L.J. et al. Dog leucocyte antigen (DLA) class II haplotypes and risk of canine diabetes mellitus in specific dog breeds. Canine Genet Epidemiol 7, 15 (2020). https://doi.org/10.1186/s40575-020-00093-9

Download citation

Keywords

  • Diabetes mellitus
  • Canine
  • Genetics
  • Dog leucocyte antigen